Skip to content
DataLookout
Menu

Merck (MSD) clinical trial pipeline

Get alerts when Merck (MSD)'s trials change
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-19

What changed in the last 30 days

88 trials changed in the last 30 days: 1 stopped, 22 with notable changes, 65 with minor changes only.

  1. Minor: Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) Trial sites expanded: 314 → 317 locations Merck Sharp & Dohme LLCPhase 3 NCT06393374
  2. Notable: MK-6916 · Pain After Bunion Removal Surgery (MK-6916-007) Recruitment opened Merck Sharp & Dohme LLCPhase 2 NCT07862595
  3. Minor: Enlicitide · High Cholesterol (MK-0616-037) Trial completed Merck Sharp & Dohme LLCPhase 3 NCT07216482
  4. Minor: Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04) Trial sites expanded: 11 → 18 locations Merck Sharp & Dohme LLCPhase 3 NCT07776691
  5. Minor: Sacituzumab Tirumotecan (Sac-TMT, MK-2870) · Breast Cancer (MK-2870-032) Trial sites expanded: 335 → 338 locations Merck Sharp & Dohme LLCPhase 3 NCT06966700
  6. Minor: TroFuse-031 · Sacituzumab Tirumotecan (Sac-TMT, MK-2870) · Urothelial Cancer (MK-2870-031) Trial sites expanded: 111 → 117 locations Merck Sharp & Dohme LLCPhase 3 NCT07419295
  7. Minor: INTerpath-014 · Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014) Trial sites expanded: 124 → 129 locations Merck Sharp & Dohme LLCPhase 3 NCT07513376
  8. Minor: Follow-up of Broad Spectrum Human Papillomavirus (HPV) Vaccine Study in Women (V503-021) Trial sites expanded: 0 → 13 locations Merck Sharp & Dohme LLCNot specified NCT02653118
  9. Notable: Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents · High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057) Results posted: Nov 13, 2026 Merck Sharp & Dohme LLCPhase 2 NCT02625961
  10. Minor: Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments · Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008) Trial completed Merck Sharp & Dohme LLCPhase 2 NCT04895722
  11. Minor: Bomedemstat · Polycythemia Vera (MK-3543-025) Trial sites expanded: 5 → 8 locations Merck Sharp & Dohme LLCPhase 2/3 NCT07722611
  12. Minor: Raludotatug Deruxtecan · Ovarian Cancer (MK-5909-003) Trial sites expanded: 39 → 42 locations Merck Sharp & Dohme LLCPhase 1/2 NCT06843447
  13. Minor: WaveSpan-008 · MK-1045 · Non-Hodgkin Lymphoma (MK-1045-008) Trial sites expanded: 52 → 56 locations Merck Sharp & Dohme LLCPhase 1/2 NCT07519772
  14. Minor: Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) · PH-COPD Study completion moved earlier from Oct 8, 2029 to May 1, 2027 Merck Sharp & Dohme LLCPhase 2 NCT05612035
  15. Notable: EXPrESSIVE-18 · Alimatravir (MK-8527) in Transgender (Trans) and Gender Diverse Individuals on Gender-affirming Hormone Therapy and at Low Likelihood of Human Immunodeficiency Virus (HIV)-1 Exposure (MK-8527-018) Recruitment opened Merck Sharp & Dohme LLCPhase 2 NCT07850609
  16. Minor: Tulisokibart (MK-7240) · Radiographic Axial Spondyloarthritis (MK-7240-013) Enrollment closed, study ongoing Merck Sharp & Dohme LLCPhase 2 NCT07133633
  17. Minor: MK-8527 in Healthy Participants (MK-8527-021) Trial completed Merck Sharp & Dohme LLCPhase 1 NCT07661108
  18. Minor: V540D in Healthy Adults (V540D-004) Primary and study completion pushed from Nov 30, 2026 to Jan 29, 2027 Merck Sharp & Dohme LLCPhase 1 NCT06688058
  19. Minor: Calderasib (MK-1084) With Targeted Therapy and Chemotherapy · Colorectal Cancer (MK-1084-012/KANDLELIT-012) Trial sites expanded: 243 → 247 locations Merck Sharp & Dohme LLCPhase 3 NCT06997497
  20. Minor: KANDLELIT-013 · MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013) Trial sites expanded: 120 → 125 locations Merck Sharp & Dohme LLCPhase 3 NCT07431827
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

New trial filings, last 30 days

First postedTrialPhaseStatus
2026-11-16 NCT07939399 A Study of V951A in Healthy Participants (V951A-001) Phase 1 Not Yet Recruiting
2026-11-06 NCT07922174 A Clinical Trial of MK-6916 in Participants With Moderate and Severe Kidney Disease… Phase 1 Not Yet Recruiting
2026-11-05 NCT07917754 A Clinical Trial of MK-1045 With Zilovertamab Vedotin in Participants With Diffuse Large… Phase 2/3 Not Yet Recruiting
2026-11-05 NCT07919028 A Clinical Trial of MK-7602 in Healthy Volunteers (MK-7602-006) Phase 1 Not Yet Recruiting
2026-11-02 NCT07908524 MK-2870-U01 Substudy 1: A Clinical Trial of Sacituzumab Tirumotecan to Treat Prostate… Phase 1/2 Not Yet Recruiting
2026-11-02 NCT07908537 A Clinical Trial of Gocatamig (MK-6070) With Durvalumab in Participants With Small Cell… Phase 3 Not Yet Recruiting
2026-10-28 NCT07899905 A Clinical Study of MK-7962 in Chinese Participants With Pulmonary Arterial Hypertension… Phase 4 Not Yet Recruiting
2026-10-26 NCT07895524 A Clinical Trial of MK-8690 in Participants With Rheumatoid Arthritis (MK-8690-004) Phase 2 Not Yet Recruiting

Active trials by phase

Phase 1
34
Phase 1/2
35
Phase 2
58
Phase 2/3
8
Phase 3
100
Phase 4
3
Not charted: 2 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

Disease areas by active trials, top 10 of 49

Get alerts when Merck (MSD)'s trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.
Start monitoring free